Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kopon, Adam
VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease	Recruiting	4	304	Europe, Canada, US, RoW	Vedolizumab	Alimentiv Inc., Takeda	Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn	01/27	09/28
VERDICT, NCT04259138: Determination of the Optimal Treatment Target in Ulcerative Colitis	Active, not recruiting	4	672	Europe, Canada, US, RoW	Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C	Alimentiv Inc., Takeda Development Center Americas, Inc.	Colitis, Ulcerative	03/26	03/26
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease	Recruiting	2	268	Europe, Canada, Japan, US, RoW	TAK-279, Zasocitinib, Placebo	Takeda	Crohn's Disease	09/26	07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis	Recruiting	2	207	Europe, Canada, Japan, US, RoW	TAK-279, Zasocitinib, Placebo	Takeda	Ulcerative Colitis	09/26	08/27
Kriks, Daria
VERDICT, NCT04259138: Determination of the Optimal Treatment Target in Ulcerative Colitis	Active, not recruiting	4	672	Europe, Canada, US, RoW	Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C	Alimentiv Inc., Takeda Development Center Americas, Inc.	Colitis, Ulcerative	03/26	03/26